Views & Analysis International benchmarking and NICE Is NICE willing to change, or is it inflexible? It is being pressed to compare itself to other HTA organisations.
UK & Europe NICE says Otezla's bargain price offsets lower efficacy Otezla cheap and convenient, but less effective than rivals, says NICE.
News NICE rejects Keytruda in lung cancer, points to price and da... Cancer immunotherapy too expensive.
News AZ's Tagrisso first to be funded through new Cancer Drugs Fu... New-look CDF pays for lung drug Tagrisso
Oncology On the benefits of earlier oncological intervention, with Jo... As ESMO 2026 came to a close, pharmaphorum web editor Nicole Raleigh spoke with Johnson & Johnson Innovative Medicine’s Carolyn Sousa and Henar Hevia
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
